Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke | Yasuo Ohashi | Michael Gnant | David Cameron | Andreas Makris | Jack Cuzick | Caroline Lohrisch | Hirofumi Mukai | Bernard Asselain | Mitch Dowsett | Jonas Bergh | Reshma Jagsi | Norman Wolmark | Alan Coates | Jan Bogaerts | Francesco Boccardo | Larry Norton | Raimund Jakesz | John Forbes | Seth Steinberg | Cornelis van de Velde | Rosie Bradley | S. Steinberg | E. Rutgers | E. Winer | J. Cuzick | J. Forbes | J. Bergh | R. Peto | T. Powles | M. Dowsett | R. Gelber | A. Tutt | M. Piccart | R. Jagsi | T. Whelan | L. Norton | J. Ragaz | S. Paik | J. Bryant | J. Costantino | N. Wolmark | M. Gnant | J. Bogaerts | A. Goldhirsch | W. Barlow | A. Makris | J. Ingle | R. Gray | C. V. D. van de Velde | J. Braybrooke | G. Viale | J. Bartlett | S. Loibl | J. Sparano | M. Regan | S. Swain | H. Mukai | J. Godwin | A. Coates | Y. Ohashi | B. Asselain | L. Pierce | L. Mauriac | D. Cameron | R. Jakesz | D. Hayes | P. Ravdin | P. Mcgale | G. Bonadonna | E. Mamounas | B. Fisher | J. A. van der Hage | D. Dodwell | C. Davies | G. von Minckwitz | L. Gianni | C. Lohrisch | D. Slamon | N. Davidson | P. Goodwin | R. C. Coombes | W. Janni | J. Bliss | J. Gazet | F. Boccardo | P. Valagussa | M. Clarke | V. Evans | C. Hill | L. Ford | I. Olivotto | C. Correa | M. Ewertz | E. Brain | N. Wilcken | S. James | T. McHugh | D. Danforth | J. Zujewski | M. Zambetti | Miguel Martín | A. Di Leo | V. Raina | R. Coleman | Carolyn W. Taylor | P. Poortmans | S. Scholl | Clare Boddington | Giuseppe Viale | Milvia Zambetti | Emiel Rutgers | Robert Coleman | Tim Whelan | Richard Peto | Luca Gianni | Gianni Bonadonna | Martine Piccart | Aron Goldhirsch | Dennis Slamon | Gunter von Minckwitz | Marianne Ewertz | Etienne Brain | Louis Mauriac | Zulian Liu | David Dodwell | Bernard Fisher | Sibylle Loibl | Wolfgang Janni | Richard Gelber | Catherine Hill | Paul McGale | Pinuccia Valagussa | John Bryant | Simon Read | Richard Gray | David Danforth | Trevor Powles | Soon Paik | P. Broet | Hui Liu | R. Bradley | G. Mannu | Jon Godwin | Eric Winer | Angelo Di Leo | Jo Anne Zujewski | John Bartlett | Joseph Ragaz | Eleftherios Mamounas | Philip Poortmans | Peter Ravdin | Ivo Olivotto | Suzy Scholl | Candace Correa | Daniel Hayes | Vinod Raina | Jos van der Hage | Lori Pierce | Christina Davies | Nicholas Wilcken | William Barlow | H. Pan | Yaochen Wang | Judith Bliss | Miguel Martín | Philippe Broet | James Ingle | Hongchao Pan | Bernard William John Jonas Elizabeth Judith Francesco Clar Asselain Barlow Bartlett Bergh Bergsten-N | Elizabeth Bergsten-Nordström | Clare Boddington | Jeremy Braybrooke | Julie Burrett | Raoul Charles Coombes | Joe Costantino | Nancy Davidson | Lucy Davies | Fran Duane | Vaughan Evans | Leslie Ford | Jean-Claude Gazet | Lucy Gettins | Pamela Goodwin | Sam James | Hui Liu | Zulian Liu | Liz MacKinnon | Gurdeep Mannu | Simone Mathoulin | Theresa McHugh | Philip Morris | Kathy Pritchard | Meredith Regan | John Robertson | Lidija Sölkner | Joseph Sparano | Rosemary Sutcliffe | Sandra Swain | Carolyn Taylor | Andrew Tutt | Yaochen Wang | Zhe Wang | Xiang Wang | William Wood | J. Burrett | F. Duane | Zhe Wang | L. Davies | L. Sölkner | Lucy Gettins | P. Morris | Simon Read | E. Bergsten-Nordström | J. Robertson | Xiang Wang | S. Mathoulin | R. Sutcliffe | K. Pritchard | Bernard William John Jonas Elizabeth Judith Francesco Clar Asselain Barlow Bartlett Bergh Bergsten-N | L. MacKinnon | William Wood | C. Taylor | R. Coombes | W. Wood

[1]  N. Harbeck,et al.  St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment , 2017, Breast Care.

[2]  C. Gross,et al.  Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States , 2015, Cancer.

[3]  Richard D Riley,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement , 2015 .

[4]  R. Rouzier,et al.  Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey , 2015, Annals of Surgical Oncology.

[5]  G. Nieuwenhuijzen,et al.  166. Patterns of care in the administration of neoadjuvant chemotherapy for breast cancer: A population based study , 2014 .

[6]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[7]  William J. Gradishar,et al.  Response-Guided Neoadjuvant Chemotherapy for Breast Cancer , 2013 .

[8]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[10]  J. Baselga,et al.  Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Greil,et al.  The potential risk of neoadjuvant chemotherapy in breast cancer patients—results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07) , 2008, Breast Cancer Research and Treatment.

[12]  Norman Wolmark,et al.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[14]  A. Seidman.  Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis , 2006 .

[15]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[16]  M. Plummer.  Improved estimates of floating absolute risk , 2004, Statistics in medicine.

[17]  S. Steinberg,et al.  Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial , 2003, Annals of Surgical Oncology.

[18]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[19]  C. V. D. van de Velde,et al.  Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Gray,et al.  Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  T. Pope,et al.  Sonographically guided clip placement facilitates localization of breast cancer after neoadjuvant chemotherapy. , 2000, AJR. American journal of roentgenology.

[22]  G. MacGrogan,et al.  Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  T. Powles,et al.  Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Asselain,et al.  Neoadjuvant chemotherapy in operable breast cancer. , 1991, European journal of cancer.

[25]  B. Asselain,et al.  Neoadjuvant chemotherapy in operabla breast cancer , 1991 .

[26]  R. Gelber,et al.  Improved methodology for analyzing local and distant recurrence. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  N Gunduz,et al.  Presence of a growth-stimulating factor in serum following primary tumor removal in mice. , 1989, Cancer research.

[28]  A R Feinstein,et al.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.

[29]  R. K. Knight,et al.  Combined chemotherapy and radiotherapy for locally advanced breast cancer. , 1980, European journal of cancer.